Navigation Links
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Date:9/22/2009

revent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies is not known and warrant further investigation in a broad spectrum of tumors.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Details on the studies and the abstract #7105 can be found on the ECCO 15 - 34th ESMO website: http://www.ecco-org.eu/Conferences-and-Events/ECCO-15/page.aspx/216.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever t
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 A new report ... Industry Analysis, Trends, Opportunities, Growth and Forecast, 2014-2020", forecasts ... by 2020. The secondary syphilis testing would continue to ... Latin America , Middle East ... accounted for about 43% revenue share of the global ...
(Date:5/28/2015)... -- The recent flurry of PBM mergers and acquisitions ... to identify a pharmacy benefit manager that isn,t ... pharmacy chain, or other potentially conflicting entity. ... Rite Aid,s $2 billion acquisition of EnvisionRx, and ... billion are just the latest examples of the ...
(Date:5/28/2015)... WASHINGTON , May 28, 2015 ... resolving the Commission,s antitrust suit charging Cephalon, Inc. ... sleep-disorder drug Provigil. The settlement ensures that Teva ... will make a total of $1.2 billion available ... insurers, who overpaid because of Cephalon,s illegal conduct.  ...
Breaking Medicine Technology:Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 2FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 3
... Oct. 28 Rules-Based Medicine (RBM), a leading ... of CardiovascularMAP, a research tool designed specifically to ... cardiovascular disease (CVD.) Designed in collaboration with leading ... combines biomarkers most commonly associated with CVD progression ...
... , CORONA, Calif., Oct. 28 Watson Pharmaceuticals, ... pharmaceutical company, announced today that its subsidiary Watson ... Laboratories, Inc. on outstanding patent litigation related to ... , On August 19, 2008, Barr submitted an ...
Cached Medicine Technology:Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development 2Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development 3Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... May 28, 2015 External Counterpulsation (EECP/ECP) ... all over the United States. There are a growing ... who can experience symptoms of angina and these patients ... stents and/or bypass surgery. , “No option” patients are ... coronary artery disease that is considered unacceptable for heart ...
(Date:5/28/2015)... 28, 2015 AMVETS National Executive Director ... Commission on Care established by Congress to examine how ... , Appointed to the commission by Mitch McConnell, majority ... one of only 15 voting members on the panel, ... Accountability Act of 2014. The goal of the commission ...
(Date:5/28/2015)... Park Cities Pet Sitter is offering a 5-week ... starting Saturday, June 6th at 10:30am. The classes will ... in Dallas, with a maximum of six dogs allowed in ... with no class being held over the 4th of July ... this Intermediate-to-Advanced level class, dogs will solidify their practical behavior ...
(Date:5/28/2015)... New Jersey Plastic Surgeon and “NJ Top ... With over 30 years of experience in the ... Dr. Rafizadeh knows what it takes to achieve that ... involves the principles of proportion, harmony and balance. ... comfort and personalized care from the moment a patient ...
Breaking Medicine News(10 mins):Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3
... analysis calls gap between these and lower-tier facilities ,disappointing, ... to the top-rated hospitals in the United States have ... patients admitted to other hospitals in the country, a ... independent health-care ratings organization, the analysis of 27 procedures ...
... February 29, 2008, PALO ALTO, Calif., Jan. ... announced today that the U.S. Food and,Drug Administration ... the,response by Solvay Pharmaceuticals, Inc. to the FDA ... Capsules. The,FDA has notified Solvay Pharmaceuticals that the ...
... PRINCETON, N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ... at the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference ... The event will be,webcast live and will be available ... at http://www.medarex.com . An archived edition of the,presentation ...
... Ill., Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin ... Stock Market(R) has approved the Company,s application to,list ... ("NASDAQ"). The,Company,s common stock will commence trading on ... "ACUR"., "We are pleased to join the ...
... In hopes of gaining a better,grasp on the ... on sales training tools and techniques to,provide their sales ... year of training and preparation is critical for success, ... approximately $10,500 in,the first year of employment, more than ...
... Prizes in Annual Essay Contest, TOMS RIVER, N.J., ... of the annual "WORD About Health",Contest during a special ... contest challenged students enrolled in Toms River intermediate schools,to ... their,understanding of nutrition and drug-free living. Over 1,900 students,submitted ...
Cached Medicine News:Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:AMERIGROUP Foundation Announces Winners of 'Word About Health' Contest 2
... Solutions introduces its new multifunctional lithotripsy ... intuitive patient data management is the ... urological table. Lithoskop is an engineering ... covers all applications like lithotripsy, endourology, ...
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... of patients requiring cataract surgery following refractive ... created a challenge for surgeons, as calculating ... difficult. True corneal power following RK, ALK, ... measure by keratometry or topography. For example, ...
... just 248 grams. It boasts an ... of all rota table continuous flow ... outer diameter has been reduced to ... a large resection volume, while excellent ...
Medicine Products: